文献速递神经核医学肿瘤 PET/CT

运动障碍中的PET/CT:进展更新

PET/CT in Movement Disorders: Update.
PubMed 文献 · Semin Nucl Med · 2025-05-04

本综述汇总近5年文献,阐述创新技术与分析方法对PET在运动障碍中应用的影响。18F-FDG PET可依据特征性代谢模式区分帕金森病与非典型帕金森综合征,量化方法与代谢连接分析提高了诊断精度。靶向α-突触核蛋白、tau、神经炎症及神经递质系统的新型示踪剂正在拓展研究应用。

要点

  • 18F-FDG PET可依据特征性代谢模式区分帕金森病与非典型帕金森综合征。
  • 帕金森病典型表现为基底节、丘脑和小脑相对高代谢,非典型帕金森综合征表现为更广泛的皮质下低代谢。
  • 量化方法与代谢连接分析提高了诊断精度,多巴胺能PET评估突触前和突触后功能障碍亦受益。

核心结论

  • PET仍是研究运动障碍的基石,近期进展加深了对疾病病理生理和进展的理解。
  • 量化方法、代谢连接分析及新型示踪剂的发展不仅强化了现有认识,也为改善运动障碍的理解与管理开辟了新途径。

研究设计与样本

  • 本综述综合近期文献,主要来自近5年,以阐述创新技术和分析方法对PET在运动障碍中应用的影响。

主要发现

  • 18F-FDG PET依据特征性代谢模式区分帕金森病与非典型帕金森综合征的能力已被持续验证。
  • 帕金森病典型表现为基底节、丘脑和小脑相对高代谢,非典型帕金森综合征表现为更广泛的皮质下低代谢。
  • 量化方法和代谢连接分析等技术创新提高了诊断精度,并提供了对疾病机制的更深洞察。
  • 多巴胺能PET成像对评估突触前和突触后功能障碍至关重要,也已从这些进展中受益。

关键数值与推荐

  • 靶向帕金森病和多系统萎缩中α-突触核蛋白、进行性核上性麻痹和皮质基底节变性中tau的新型示踪剂正在研发。
  • 针对神经炎症、小胶质细胞激活以及5-羟色胺和乙酰胆碱等神经递质系统的示踪剂也在发展中。
  • PET尚未常规用于亨廷顿病或共济失调的临床评估,但研究应用正在扩大。

临床怎么用

  • 18F-FDG PET可依据特征性代谢模式用于区分帕金森病与非典型帕金森综合征。
  • 多巴胺能PET成像用于评估突触前和突触后功能障碍。
  • PET尚未常规用于亨廷顿病或共济失调的临床评估,相关应用仍限于研究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review synthesizes recent literature, primarily from the last 5 years, to highlight the impact of innovative technologies and analytical approaches on the application of positron emission tomography (PET) in movement disorders. PET remains a cornerstone for investigating these conditions, with recent advancements enhancing our understanding of disease pathophysiology and progression. Established findings, such as the ability of [18F]-fluorodeoxyglucose PET (18F-FDG PET) to differentiate Parkinson's disease (PD) from atypical parkinsonian syndromes based on characteristic metabolic patterns, have been consistently validated. PD typically presents with relative hypermetabolism in the basal ganglia, thalamus and cerebellum, while atypical parkinsonisms exhibit more widespread subcortical hypometabolism. Technological innovations, particularly in quantification methods and metabolic connectivity analysis, have improved diagnostic precision and provided deeper insights into disease mechanisms. Dopaminergic PET imaging, crucial for assessing presynaptic and postsynaptic dysfunction, has also benefited from these advances. The field is further evolving with the development of novel tracers targeting pathological hallmarks, such as alpha-synuclein in PD and multiple system atrophy (MSA), tau in progressive supranuclear palsy (PSP) and cortico-basal degeneration (CBD), and tracers for neuroinflammation, microglial activation, and neurotransmitter systems like serotonin and acetylcholine. While PET is not yet routinely used for the clinical assessment of Huntington's disease or ataxia, research applications are expanding, driven by the potential of these new tracers and analytical techniques. These advancements not only reinforce existing knowledge but also open new avenues for enhancing the understanding and management of movement disorders.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nerattini M, Abenavoli EM, Berti V, et al. PET/CT in Movement Disorders: Update. Semin Nucl Med. 2025. PMID: 40320359. doi:10.1053/j.semnuclmed.2025.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。